Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:NVNO NASDAQ:PETV NASDAQ:TMDIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.34$4.27$1.03▼$32.10$55.56M3.45431,191 shs229,477 shsNVNOenVVeno Medical$10.68-2.6%$10.90$8.67▼$196.70$7.32M1.0814,280 shs11,505 shsPETVPetVivo$0.78$0.76$0.60▼$1.69$28.16M1.2710,991 shs4,500 shsTMDIFTitan Medical$0.20-2.2%$0.28$0.03▼$1.00$23.25M1.2674,785 shs36,407 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+14.10%-19.58%+141.63%+533,999,900.00%NVNOenVVeno Medical0.00%+8.71%-18.16%-7.13%-90.89%PETVPetVivo0.00%+6.56%-2.38%+11.43%-2.50%TMDIFTitan Medical0.00%+1.44%-38.21%-32.42%-25.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.34$4.27$1.03▼$32.10$55.56M3.45431,191 shs229,477 shsNVNOenVVeno Medical$10.68-2.6%$10.90$8.67▼$196.70$7.32M1.0814,280 shs11,505 shsPETVPetVivo$0.78$0.76$0.60▼$1.69$28.16M1.2710,991 shs4,500 shsTMDIFTitan Medical$0.20-2.2%$0.28$0.03▼$1.00$23.25M1.2674,785 shs36,407 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+14.10%-19.58%+141.63%+533,999,900.00%NVNOenVVeno Medical0.00%+8.71%-18.16%-7.13%-90.89%PETVPetVivo0.00%+6.56%-2.38%+11.43%-2.50%TMDIFTitan Medical0.00%+1.44%-38.21%-32.42%-25.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/ANVNOenVVeno Medical 1.50ReduceN/AN/APETVPetVivo 0.00N/AN/AN/ATMDIFTitan Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVNO, PETV, AGPU, and TMDIF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026NVNOenVVeno Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$120K462.80N/AN/A$3.87 per share1.38NVNOenVVeno MedicalN/AN/AN/AN/A$35.57 per shareN/APETVPetVivo$1.05M26.92N/AN/A($0.03) per share-26.00TMDIFTitan Medical$17.63M1.32$10.20 per share0.02$1.05 per share0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$8.18N/AN/AN/A-470,383.31%-7,363.67%-626.32%N/ANVNOenVVeno Medical-$19.47M-$25.54N/AN/AN/AN/A-66.39%-60.42%7/30/2026 (Estimated)PETVPetVivo-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%6/25/2026 (Estimated)TMDIFTitan Medical$6.95M$0.05N/AN/AN/AN/A-82.31%-51.47%N/ALatest NVNO, PETV, AGPU, and TMDIF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AGPUPredictive OncologyN/A-$0.36N/A-$0.36N/A$0.04 million5/7/2026Q1 2026NVNOenVVeno Medical-$8.40-$5.89+$2.51-$5.89$0.50 millionN/A3/31/2026Q4 2025AGPUPredictive OncologyN/A$122.75N/A$122.75N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A8.8910.02NVNOenVVeno MedicalN/A11.8911.89PETVPetVivo0.020.420.47TMDIFTitan MedicalN/A3.733.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%NVNOenVVeno Medical34.71%PETVPetVivo24.55%TMDIFTitan Medical0.03%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%NVNOenVVeno Medical15.00%PETVPetVivo10.84%TMDIFTitan Medical0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology3010.40 million10.28 millionN/ANVNOenVVeno Medical30670,000568,000OptionablePETVPetVivo2036.10 million19.06 millionNot OptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionableNVNO, PETV, AGPU, and TMDIF HeadlinesRecent News About These CompaniesDefiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Titan Medical (NASDAQ:TMDIF) Head to Head ContrastMay 18, 2026 | americanbankingnews.comTitan Medical (NASDAQ:TMDIF) and Assure (OTCMKTS:IONM) Head to Head ComparisonMay 16, 2026 | americanbankingnews.comTitan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare StaffingApril 29, 2025 | businesswire.comTitan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing ServicesApril 29, 2025 | businesswire.comTitan MRI acquires High Field MRI, expanding Titan MRI's service to North Central FloridaDecember 3, 2024 | msn.comAttack on Titan movie release date, trailer, changes, and everything else we know about The Last AttackNovember 6, 2024 | gamesradar.comGConavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business CombinationOctober 11, 2024 | globenewswire.comTitan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the TransactionOctober 8, 2024 | globenewswire.comTitan Announces Resignations of DirectorsOctober 2, 2024 | globenewswire.comTitan Reports Voting Results from 2023 Annual General and Special MeetingSeptember 30, 2024 | globenewswire.comTitan Medical begins process to move to the TSX Venture ExchangeSeptember 30, 2024 | globenewswire.comConavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and ConaviSeptember 26, 2024 | globenewswire.comProxy Deadline Thursday September 26, 2024September 25, 2024 | globenewswire.comProxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 19, 2024 | globenewswire.comA key employee says the Titan sub tragedy could have been preventedSeptember 18, 2024 | postregister.comPTitan Announces Conavi Medical to Present Overview at Titan Q&A SessionSeptember 16, 2024 | globenewswire.comIndependent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 16, 2024 | globenewswire.comTitan Announces Q&A Session with ShareholdersSeptember 9, 2024 | globenewswire.comTitan Announces Filing of the Management Information Circular.September 6, 2024 | globenewswire.comTitan Medical | Morning BlendSeptember 3, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVNO, PETV, AGPU, and TMDIF Company DescriptionsPredictive Oncology NASDAQ:AGPU$5.34 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.40 +0.06 (+1.05%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.enVVeno Medical NASDAQ:NVNO$10.68 -0.28 (-2.55%) Closing price 05/22/2026 03:50 PM EasternExtended Trading$9.60 -1.08 (-10.10%) As of 05/22/2026 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. PetVivo NASDAQ:PETV$0.78 0.00 (0.00%) As of 05/22/2026 12:56 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Titan Medical NASDAQ:TMDIF$0.20 0.00 (-2.21%) As of 05/22/2026Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
